Evaluation of Valved Holding Chambers Simulating Repurposing Use of Ciclesonide Metered-dose Inhaler by Patients with Pneumonia
Achieving appropriate inhalation in patients with coronavirus disease 2019 (COVID-19) is a common challenge in the use of repurposed metered-dose inhaler (MDI) formulations. The purpose of this study was to evaluate the effect of five valved holding chambers (VHCs) on the inhalation of ciclesonide from Alvesco MDI. The aerodynamic particle size distribution of ciclesonide discharged from Alvesco MDI was evaluated using a Next Generation Impactor in the presence and absence of VHCs. The use of VHCs retained or slightly increased the amount of ciclesonide in the fine particle diameter range (aerodynamic particle size below 3 μm) (FPD) and reduced the amount at the induction port after coordinated inhalation. However, the use of VHC reduced the FPD of the formulation by increasing the time between the MDI discharge and the pump suction by various degrees among the five VHCs. These results indicated that use of the VHCs and minimizing the inhalation delay time should ensure sufficient inhalation of ciclesonide particles.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:140 |
|---|---|
| Enthalten in: |
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan - 140(2020), 12 vom: 01. Dez., Seite 1495-1500 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Yoshida, Hiroyuki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ciclesonide |
|---|
| Anmerkungen: |
Date Completed 11.12.2020 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1248/yakushi.20-00169 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315526149 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315526149 | ||
| 003 | DE-627 | ||
| 005 | 20231225155116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.1248/yakushi.20-00169 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315526149 | ||
| 035 | |a (NLM)32981902 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Yoshida, Hiroyuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of Valved Holding Chambers Simulating Repurposing Use of Ciclesonide Metered-dose Inhaler by Patients with Pneumonia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.12.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Achieving appropriate inhalation in patients with coronavirus disease 2019 (COVID-19) is a common challenge in the use of repurposed metered-dose inhaler (MDI) formulations. The purpose of this study was to evaluate the effect of five valved holding chambers (VHCs) on the inhalation of ciclesonide from Alvesco MDI. The aerodynamic particle size distribution of ciclesonide discharged from Alvesco MDI was evaluated using a Next Generation Impactor in the presence and absence of VHCs. The use of VHCs retained or slightly increased the amount of ciclesonide in the fine particle diameter range (aerodynamic particle size below 3 μm) (FPD) and reduced the amount at the induction port after coordinated inhalation. However, the use of VHC reduced the FPD of the formulation by increasing the time between the MDI discharge and the pump suction by various degrees among the five VHCs. These results indicated that use of the VHCs and minimizing the inhalation delay time should ensure sufficient inhalation of ciclesonide particles | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ciclesonide | |
| 650 | 4 | |a coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a fine particle dose | |
| 650 | 4 | |a metered-dose inhaler | |
| 650 | 4 | |a valved holding chamber | |
| 650 | 7 | |a Pregnenediones |2 NLM | |
| 650 | 7 | |a ciclesonide |2 NLM | |
| 650 | 7 | |a S59502J185 |2 NLM | |
| 700 | 1 | |a Abe, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Usui, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Izutsu, Ken-Ichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan |d 1961 |g 140(2020), 12 vom: 01. Dez., Seite 1495-1500 |w (DE-627)NLM000042153 |x 1347-5231 |7 nnns |
| 773 | 1 | 8 | |g volume:140 |g year:2020 |g number:12 |g day:01 |g month:12 |g pages:1495-1500 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1248/yakushi.20-00169 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 140 |j 2020 |e 12 |b 01 |c 12 |h 1495-1500 | ||